EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

SGLT2 Inhibitors and Liver Cirrhosis: Hype or Hope?

Olga Brusnic, Danusia Maria Onisor iD, Adrian Boicean iD, Corina Porr iD, Florin Daniel Sofonea iD, Paula Anderco, Cristian Ichim iD

Life · 21.11.2025 · 15 (12) · 1788

DOI: 10.3390/life15121788 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 21.11.2025. Verfasst von Olga Brusnic und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine VII, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Gheorghe Marinescu S…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver cirrhosis is marked by sodium and water retention, portal hypertension and sharply reduced survival after decompensation. Sodium–glucose cotransporter-2 inhibitors (SGLT2i) induce insulin-independent glycosuria and natriuresis and have proven cardio-renal benefits, prompting interest in their role as adjuncts for ascites. This review synthesizes current evidence on efficacy, safety and mechanistic plausibility of SGLT2i in cirrhosis. Observational cohorts and case series suggest that adding SGLT2i to standard diuretics increases natriuresis, lowers ascites burden and paracentesis requirements, improves weight and aminotransferases and may reduce hepatic decompensation and hepatocellular carcinoma risk. Safety remains paramount: hypotension, acute kidney injury and hepatorenal syndrome-related acute kidney injury, genitourinary infections, electrolyte disturbances and rare euglycemic ketoacidosis necessitate careful patient selection, slow titration and close monitoring, especially in decompensated disease and when combined with loop diuretics or mineralocorticoid receptor antagonists. Overall, the balance of data supports cautious optimism: SGLT2i represent a promising adjunct within protocolized care pathways for selected patients, while definitive trials powered for hepatic outcomes are still required to clarify indications, timing, dosing and long-term impact.

Schlagwörter

Stichwörter der Autor:innen

SGLT2iascitesliver cirrhosis

Autor:innen und Institutionen

  • Department of Internal Medicine VII, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Gheorghe Marinescu Street No. 38, 540136 Targu Mures, Romania.
  • Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania.
  • Faculty of Social Sciences, Lucian Blaga University of Sibiu, 550012 Sibiu, Romania.

ORCID-Profile: Danusia Maria Onisor, Adrian Boicean, Corina Porr, Florin Daniel Sofonea, Cristian Ichim

Zitieren

APA

Brusnic, O., Onisor, D. M., Boicean, A., Porr, C., Sofonea, F. D., Anderco, P., & Ichim, C. (2025). SGLT2 Inhibitors and Liver Cirrhosis: Hype or Hope?. Life, 15(12), 1788. https://doi.org/10.3390/life15121788

Vancouver

Brusnic O, Onisor DM, Boicean A, Porr C, Sofonea FD, Anderco P, et al. SGLT2 Inhibitors and Liver Cirrhosis: Hype or Hope?. Life. 2025;15(12):1788. doi:10.3390/life15121788

BibTeX
@article{Brusnic2025,
  author = {Brusnic, Olga and Onisor, Danusia Maria and Boicean, Adrian and Porr, Corina and Sofonea, Florin Daniel and Anderco, Paula and Ichim, Cristian},
  title = {SGLT2 Inhibitors and Liver Cirrhosis: Hype or Hope?},
  journal = {Life},
  year = {2025},
  volume = {15},
  number = {12},
  pages = {1788},
  doi = {10.3390/life15121788}
}
Kostenlos starten →